Concerns over Alzheimer's drug - Seroquel

[Guest guest]

For anyone taking Seroquel I urge you to read the PDR concerning this

drug. It has some very nasty side effects which can cause permanent

damage.

 

 

 

SSRI-Research@

Fri, 18 Feb 2005 19:46:32 -0500

Subject:[sSRI-Research] Concerns over Alzheimer's drug

 

 

 

 

Concerns over Alzheimer's drug

 

A drug used to treat patients with Alzheimer's disease could actually

make their condition worse, a study says.

 

Quetiapine (Seroquel) is commonly used in nursing homes to combat

agitation, a common symptom of Alzheimer's.

 

But research by Institute of Psychiatry experts in the British Medical

Journal online suggests it could significantly speed up the rate of

patients' decline.

 

However, a spokesman for AstraZeneca, which makes Seroquel, said the

drug was safe and effective.

 

 

These results show the huge and pressing need to develop new and

safe treatments for people with dementia.

Rebecca Wood, Alzheimer's Research Trust

 

Antipsychotic drugs such as quetiapine are used in up to 45% of

nursing homes to treat agitation, which is a common and distressing

symptom of dementia. They are also used to treat schizophrenia.

 

Ninety-three patients at care homes in the north-east of England who

had Alzheimer's, dementia and significant levels of agitation were

studied over six months.

 

They were split into three groups. One was given a daily dose of

quetiapine, another was given the " anti-dementia " drug rivastigmine,

and the third a dummy pill.

 

Researchers then assessed their agitation levels and cognitive

abilities, such as memory skills, throughout the study.

 

Distress

 

Forty-six patients completed cognitive assessments after six weeks.

 

The 14 who were taking quetiapine registered an average drop of around

14 points on the scale used to assess decline, compared to almost no

change for those taking the dummy pill.

 

Those who took rivastigmine showed little or no worsening of their

illness - but no improvement in symptoms compared to the dummy pill group.

 

The study is of concern to Alzheimer's researchers as there have

previously been worries about the safety of the two most commonly used

antipsychotic drugs in people with dementia, risperidone and

olanzapine, because of an increased risk of stroke.

 

But the researchers said their findings showed quetiapine should not

be used instead of other drugs for alleviating their symptoms, and

that they highlighted concerns over long term use of antipsychotics in

Alzheimer's patients.

 

Dr Clive Ballard, who led the study, said: " Behavioural problems seen

in people with dementia can be extremely distressing and present major

difficulties for both patients and caregivers.

 

" This research shows that the drug quetiapine does not help with the

agitation experienced by some patients and that it accelerates

cognitive decline.

 

" We are extremely fortunate that people are willing to volunteer for

this important research.

 

" Like us, they hope the project will lead to improved treatments for

Alzheimer's and other causes of dementia. "

 

'Too small'

 

Rebecca Wood, chief executive of the Alzheimer's Research Trust, which

funded the study, said: " These results show the huge and pressing need

to develop new and safe treatments for people with dementia.

 

" Research into Alzheimer's is severely underfunded and we desperately

need to do more to accelerate progress towards finding effective

treatments, both for the symptoms and for the underlying disease. "

 

However, a spokesman for AstraZeneca said: " The company remains

confident in Seroquel's safety and efficacy profile, with more than

eight million patients treated since its launch in 1997. "

 

He said that the sample used was too small for conclusions about the

drug's effect on cognitive decline to be made.

 

And he added: " One patient in the Seroquel arm of the study had an

unusually large negative change in cognitive assessment.

 

" Two of the placebo [dummy pill] patients and two of the rivastigmine

patients had unusually large improvements. These five patients

disproportionately influenced the results of this small study. "

 

Story from BBC NEWS:

http://news.bbc.co.uk/go/pr/fr/-/1/hi/health/4274745.stm

 

Published: 2005/02/18 01:07:45 GMT

 

© BBC MMV